Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 16

297 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
297
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

297 trials in Le Kremlin-Bicetre

Open in trial search

Anti-myelin-associated glycoprotein associated polyneuropathy

Not yet recruiting

Study of Rituximab compared to placebo in patients with anti-MAG neuropathy who are likely to respond well to treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Congenital absence of bile ducts

Not recruiting

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Hypocalcaemia

Not recruiting

Study of encaleret compared to standard care in patients with autosomal dominant hypocalcemia type 1

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alfacalcidol
  • Sponsor:Calcilytix Therapeutics Inc.

Pulmonary arterial hypertension

Not recruiting

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Chronic kidney disease

Not recruiting

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Gastroenterology Research

Innovative studies exploring treatments for inflammatory bowel diseases, with multiple trials investigating fecal microbiota transplantation as a therapeutic approach for Crohn's disease and ulcerative colitis. Research focuses on maintaining remission and improving patient outcomes.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Microbiota-Based Therapies
02 Neurology Studies

Clinical research targeting neurological conditions, including trials for Myasthenia Gravis and innovative treatments for aneurysmal subarachnoid hemorrhage. Studies aim to improve daily living activities and patient outcomes.

  • Myasthenia Gravis Treatment
  • Subarachnoid Hemorrhage Management
  • Neurological Disorders
03 Immunology & Rheumatology

Comprehensive research into autoimmune conditions, including studies on rheumatoid arthritis and Sjögren's syndrome. Trials evaluate novel therapeutic approaches and maintenance treatments for improved disease management.

  • Rheumatoid Arthritis Therapies
  • Sjögren's Syndrome Research
  • Immune System Disorders
04 Pulmonary Medicine

Advanced research in respiratory conditions, including studies on pulmonary hypertension, severe asthma, and interstitial lung disease. Trials focus on evaluating new treatments and improving patient care strategies.

  • Pulmonary Hypertension
  • Severe Asthma Management
  • Lung Fibrosis Treatment
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.